Nucleai
Nucleai is an AI-powered digital pathology company dedicated to transforming drug development and clinical treatment decisions. As the first in the world to deploy an AI pathology algorithm for prospective trial enrollment, Nucleai provides pharmaceutical companies with actionable insights that enhance their biomarker and diagnostic strategies for next-generation therapeutics, including antibody-drug conjugates (ADCs), multispecifics, and novel IO drugs. Based in Israel and Chicago, Nucleai is revolutionizing personalized medicine and advancing healthcare.
